Heterogeneous Role of Caspase-8 in Fenretinide-Induced Apoptosis in Epithelial Ovarian Carcinoma Cell Lines

Molecular Pharmacology

Volumn 64, Issue 6, 2003, Pages 1434-1443

  Kalli, Kimberly R ^a,b   Devine, Kathryn E ^b   Cabot, Myles C ^c   Arnt, Christina R ^b   Heldebrant, Michael P ^b   Svingen, Phyllis A ^b   Erlichman, Charles ^b   Hartmann, Lynn C ^a,b   Conover, Cheryl A ^a,b   Kaufmann, Scott H ^a,b  

^a MAYO CLINIC CANCER CENTER   (United States)

^b MAYO CLINIC   (United States)

^c JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOTIC PROTEASE ACTIVATING FACTOR 1; CASPASE 10; CASPASE 8; CASPASE 8 INHIBITOR; CASPASE 9; CERAMIDE; COMPLEMENTARY DNA; CYTOKINE RESPONSE MODIFIER A; DEATH RECEPTOR 5; DNA FRAGMENT; FAS LIGAND; FENRETINIDE; FLICE INHIBITORY PROTEIN; PACLITAXEL; PROCASPASE 10; PROCASPASE 8; PROCASPASE 9; RETINOID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME SUBSTRATE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR CELL LINE;

APOPTOSIS; CASPASE 8; CASPASE 9; CASPASES; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FEMALE; FENRETINIDE; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 10744230535     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.64.6.1434     Document Type: Article

References (40)

1. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, and Gronemeyer H (2001) Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 7:680-686.
2. Chiantore MV, Giandomenico V, and De Luca LM (1999) Carcinoma cell lines resistant for growth inhibition and apoptosis to retinoic acid are responsive to 4-hydroxyphenyl-retinamide: correlation with tissue transglutaminase. Biochem Biophys Res Commun 254:636-641.
3. Clifford JL, Menter DG, Wang M, Lotan R, and Lippman SM (1999) Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res 59:14-18.
4. Conover CA, Hartmann LC, Bradley S, Stalboerger P, Klee GG, Kalli KR, and Jenkins RB (1998) Biological characterization of human epithelial ovarian carcinoma cells in primary culture: the insulin-like growth factor system. Exp Cell Res 238:439-449.
5. De Palo G, Mariani L, Camerini T, Marubini E, Formelli F, Pasini B, Decensi A, and Veronesi U (2002) Effect of fenretinide on ovarian carcinoma occurrence. Gynecol Oncol 86:24-27.
6. De Palo G, Veronesi U, Camerini T, Formelli F, Mascotti G, Boni C, Fosser V, Del Vecchio M, Campa T, Costa A, et al. (1995) Can fenretinide protect women against ovarian cancer? J Natl Cancer Inst 87:146-147.
7. Delia D, Aiello A, Lombardi L, Pelicci PG, Grignani F, Grignani F, Formelli F, Menard S, Costa A, and Veronesi U (1993) N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid. Cancer Res 53:6036-6041.
8. DiPietrantonio AM, Hsieh T-C, Juan G, Traganos F, Darzynkiewicz Z, and Wu JM (2000) Fenretinide-induced caspase 3 activity involves increased protein stability in a mechanism distinct from reactive oxygen species elevation. Cancer Res 60:4331-4335.
9. Fanjul AN, Delia D, Pierotti MA, Rideout D, Qiu J, and Pfahl M (1996) 4-Hydroxyphenyl retinamide is a highly selective activator of retinoid receptors. J Biol Chem 271:22441-22446.
10. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, and Thornberry NA (1998) Inhibition of Human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 273:32608-32613.
11. Hail N Jr and Lotan R (2001) Mitochondrial respiration is uniquely associated with the prooxidant and apoptotic effects of N-(4-hydroxyphenyl)retinamide. J Biol Chem 276:45614-45621.
12. Herr I and Debatin K-M (2001) Cellular stress response and apoptosis in cancer therapy. Blood 98:2603-2614.
13. Ito Y, Pandey P, Place A, Sporn MB, Gribble GW, Honda TKS, and Kufe D (2000) The novel triterpenoid 2-cyano-3, 12-dioxoolean-1, 9-dien-28-oic acid induces apoptosis of human myeloid leukemia cells by a caspase-8-dependent mechanism. Cell Growth Differ 11:261-267.
14. Kottke TJ, Blajeski AL, Meng X, Svingen PA, Ruchaud S, Mesner PW Jr, Boerner SA, Samejima K, Henriquez NV, Chilcote TJ, et al. (2002) Lack of correlation between caspase activation and caspase activity assays in paclitaxel-treated MCF-7 breast cancer cells. J Biol Chem 277:804-815.
15. Krueger A, Baumann S, Krammer PH, and Kirchhoff S (2001) FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol 21:8247-8254.
16. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC, and Reynolds CP (1999) Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)retinamide in neuroblastoma cell lines. J Natl Cancer Inst 91:1138-1146.
17. Meng XW, Heldebrant MP, and Kaufmann SH (2002) Phorbol-12-myristate 13-acetate inhibits death receptor-mediated apoptosis in Jurkat cells by disrupting FADD recruitment. J Biol Chem 277:3776-3783.
18. Micheau O, Solary E, Hammann A, and Dimanche-Boitrel M-T (1999) Fas ligand-independent, FADD-mediated action of the Fas death pathway by anticancer drugs. J Biol Chem 274:7987-7992.
19. Mow BF, Blajeski AL, Chandra J, and Kaufmann SH (2001) Apoptosis and the Response to Anticancer Therapy. Curr Opin Oncol 13:453-462.
20. Newton K and Strasser A (2000) Ionizing radiation and chemotherapeutic drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/MORT1 signaling. Implications for cancer therapy. J Exp Med 191:195-200.
21. Perkins C, Kim CN, Fang G, and Bhalla KN (1998) Overexpression of Apaf-1 promotes apoptosis of untreated and paclitaxel- or etoposide-treated HL-60 cells. Cancer Res 58:4561-4566.
22. Prinetti A, Basso L, Appierto V, Villani MG, Valsecchi M, Loberto N, Prioni S, Chigorno V, Cavadini E, Formelli F, et al. (2003) Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J Biol Chem 278:5574-5583.
23. Puduvalli VK, Saito Y, Xu R, Kouraklis GP, Levin VA, and Kyritsis AP (1999) Fenretinide activates caspases and induces apoptosis in gliomas. Clin Cancer Res 5:2230-2235.
24. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, Debatin KM, Krammer PH, and Peter ME (1998) Two CD95 (APO-1)/Fas) signaling pathways. EMBO (Eur Mol Biol Organ) J 17:1675-1687.
25. Shao RG, Cao CX, Nieves-Neira W, Dimanche-Boitrel MT, Solary E, and Pommier Y (2001) Activation of the Fas pathway independently of Fas ligand during apoptosis induced by camptothecin in p53 mutant human colon carcinoma cells. Oncogene 20:1852-1859.
26. Sheikh MS, Shao ZM, Li XS, Ordonez JV, Conley BA, Wu S, Dawson MI, Han QX, Chao WR, and Quick T (1995) N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma. Carcinogenesis 16:2477-2486.
27. Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang H-G, Reed JC, Nicholson DW, Alnemri ES, et al. (1999) Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8 and -10 in a caspase-9-dependent manner. J Cell Biol 144:281-292.
28. Srinivasula SM, Ahmad M, Fernandes-Alnemri T, and Alnemri ES (1998) Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. Mol Cell 1:949-957.
29. Supino R, Crosti M, Clerici M, Walters A, Cleris L, Zunino F, and Formelli F (1996) Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expression. Int J Cancer 65:491-497.
30. Suzuki S, Higuchi M, Proske RJ, Oridate N, Hong WK, and Lotan R (1999) Implication of mitochondria-derived reactive oxygen species, cytochrome c and caspase-3 in N-(4-hydroxyphenyl)retinimide-induced apoptosis in cervical carcinoma cells. Oneogene 18:6380-6387.
31. Swerdlow RD, Zwiebel JA, Gravell AE, and Cheson BD (2001) Current clinical trials of fenretinide. Oncology 15:1595-1598.
32. Thorburn J, Bender LM, Morgan MJ, and Thorburn A (2003a) Caspase- and serine protease-dependent apoptosis by the death domain of FADD in normal epithelial cells. Mol Biol Cell 14:67-77.
33. Thorburn J, Frankel AE, and Thorburn A (2003b) Apoptosis by leukemia cell-targeted diphtheria toxin occurs via receptor-independent activation of Fas-associated death domain protein. Clin Cancer Res 9:861-865.
34. Ulukaya E, Pirianov G, Kurt MA, Wood EJ, and Mehmet H (2003) Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation. Cell Death Differ 10:856-859.
35. Um SJ, Lee SY, Kim EJ, Han HS, Koh YM, Hong KJ, Sin HS, and Park JS (2001) Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells. Cancer Lett 174:127-134.
36. van den Hoff MJB, Moorman AFM, and Lamers WH (1992) Electroporation in "intracellular" buffer increases cell survival. Nucleic Acids Res 20:2902.
37. Wang H, Maurer BJ, Reynolds CP, and Cabot MC (2001) N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res 61:5201-5205.
38. Wen J, Ramadevi N, Nguyen D, Perkins CL, Worthington E, and Bhalla KN (2000) Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 96:3900-3906.
39. You KR, Shin MN, Park RK, Lee SO, and Kim DG (2001) Activation of caspase-8 during N-(4-hydroxyphenyl)retinamide-induced apoptosis in Fas-defective hepatoma cells. Hepatology 34:1119-1127.
40. Zhou Q and Salvesen GS (2000) Viral caspase inhibitors CrmA and p35. Methods Enzymol 322:143-154.